HAP Trading’s Ocular Therapeutix OCUL Stock Holding History

HAP Trading’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,700	Closed	-$5K	–	1153
2016 Q3	$5K	Buy	+10,700	New	+$65.2K	﹤0.01%	1040

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HAP Trading's OCUL Position: Q1 2021 in Review

HAP Trading sold out of Ocular Therapeutix (OCUL) in Q1 2021, closing a stake of 63,034 shares — an estimated $1.3M sold.

HAP Trading first reported a position in OCUL in Q4 2020 and held it in 1 quarter. The position peaked at $1.3M in Q4 2020. 154 funds tracked by Wall St. Rank hold OCUL as of Q1 2021.

HAP Trading reported no remaining Ocular Therapeutix position as of Q1 2021 after selling out during the quarter.
HAP Trading sold 63,034 Ocular Therapeutix shares in Q1 2021, an estimated $1.3M.
HAP Trading first reported a position in Ocular Therapeutix in Q4 2020 and held it in 1 quarter.
HAP Trading's Ocular Therapeutix position peaked at $1.3M in Q4 2020.
154 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2021.

Based on HAP Trading's 13F filing for Q1 2021, filed 14 May 2021.